Illustrative image – not actual.Emcure Pharmaceuticals is investing Rs.40 crore to set up a formulations plant at Hinjewadi near Pune. The plant, which is expected to become operational in November 2003, will produce tablets (3,600 million nos.). and capsules (1,600 million nos.).
Emcure is also setting up a biotech facility near Pune, entailing an investment of Rs.35 crore. The plant, producing bio-generic drugs, is scheduled for commissioning in March 2004. The proposed products include TNK TPA (tissue plasminogen activator), which would dissolve blood clots in the heart and G-CSF (granulocyte colony stimulating factor), which would stimulate activity of cells in the bone marrow that had been reduced due to chemotherapy.
The company would also take up manufacture of erythropoeitin that stimulate the production of red blood corpuscles (RBCs) in the bone marrow in anaemic patients. It may be noted that Emcure is currently engaged in marketing of erythropoeitin.
